Interferon-beta/nivolumab/pembrolizumabGastritis, liver dysfunction and lack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2037卷 / 1期

关键词：

D O I：

10.1007/s40278-024-71909-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：216 / 216

相关论文

共 50 条

[31] Ipilimumab/nivolumab/pembrolizumabVarious toxicities and lack of efficacy: case report
Reactions Weekly, 2022, 1917 (1) : 328 - 328
[32] Nivolumab/pazopanib/pembrolizumabVarious toxicities and lack of efficacy: case report
Reactions Weekly, 2025, 2047 (1) : 351 - 351
[33] Methylprednisolone/nivolumab/prednisoloneOptic perineuritis and lack of efficacy: case report
Reactions Weekly, 2021, 1879 (1) : 230 - 230
[34] Carboplatin/nivolumab/paclitaxelVarious toxicities and lack of efficacy: case report
Reactions Weekly, 2021, 1871 (1) : 113 - 113
[35] Nivolumab/prednisoloneExacerbation of bullous pemphigoid and lack of efficacy: case report
Reactions Weekly, 2025, 2042 (1) : 394 - 394
[36] Nivolumab/prednisoneLichen planus pemphigoides and lack of efficacy: case report
Reactions Weekly, 2023, 1946 (1) : 437 - 437
[37] Nivolumab/sunitinibThyroid and endocrine disorders and Lack of efficacy: case report
Reactions Weekly, 2022, 1896 (1) : 365 - 365
[38] Cetuximab/nivolumab/pembrolizumabColitis, hyperthyroidism and lack of efficacy: case report
Reactions Weekly, 2022, 1913 (1) : 138 - 138
[39] Axitinib/nivolumab/pazopanibVarious toxicities and lack of efficacy: case report
Reactions Weekly, 2023, 1950 (1) : 75 - 75
[40] Cefuroxime/interferon beta 1aThrombotic microangiopathy and lack of efficacy: case report
Reactions Weekly, 2022, 1924 (1) : 151 - 151

← 1 2 3 4 5 →